1. PS7:133 Exposure-response modelling and exposure-safety modelling analyses in two phase ii studies of atacicept in sle. (21st March 2018) Authors: Papasouliotis, O; Yalkinoglu, O; Vazquez Mateo, C; Wax, S; Kao, A; Chang, P; Fleuranceau-Morel, P; Mahnke, L Journal: Lupus science & medicine Issue: Volume 5(2018)Supplement 1 Page Start: A101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S7A:4 Reduction of systemic lupus flares by atacicept in a randomised, placebo-controlled, phase iib study (address ii) and its extension study. (21st March 2018) Authors: Wallace, DJ; Isenberg, DA; Kao, A; Vazquez-Mateo, C; Fleuranceau-Morel, P; Chang, P; Merril, JT Journal: Lupus science & medicine Issue: Volume 5(2018)Supplement 1 Page Start: A25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S7A:5 Sri response, attainment of low disease activity and safety in patients with systemic lupus treated with atacicept in a phase iib study (address ii). (21st March 2018) Authors: Merril, JT; Morand, E; Wallace, DJ; Kao, A; Vazquez-Mateo, C; Chang, P; Fleuranceau-Morel, P; Isenberg, DA Journal: Lupus science & medicine Issue: Volume 5(2018)Supplement 1 Page Start: A26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗